The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Putilina M.V.

Pirogov Russian National Research Medical University

Teplova N.V.

Pirogov Russian National Research Medical University

Drug synergism as a basis for rational neuroprotection

Authors:

Putilina M.V., Teplova N.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(5): 17‑22

DOI: 10.17116/jnevro202212205117

Views: 10094

Downloaded: 250

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Putilina MV, Teplova NV. Drug synergism as a basis for rational neuroprotection. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(5):17‑22. (In Russ.)
https://doi.org/10.17116/jnevro202212205117

 
МСФ на ЯМ
Close metadata
Recommended articles:
Asthenic diso­rders correction with Reco­gnan. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):57-62
Resu­lts of a pilot study of the stru­cture and evaluation of the therapy for chro­nic sleep diso­rders in como­rbid patients with chro­nic cere­bral ischemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):118-126
Cognitive impairment in patients with arte­rial hype­rtension. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):41-48
Possibilities of physiotherapy in glaucomatous optic neuropathy after glaucoma surgery. Russian Annals of Ophthalmology. 2024;(3):88-94
Reco­gnan (citicoline) in the correction of asthenic and anxiety-depressive diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):43-47
Study of the practice of prescribing phenosanic acid in epilepsy acco­mpanied by asthenic diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):89-97
Neuprotection of post-acute COVID-19 cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):106-111
Pharmacological effe­cts of fonturacetam (Actitropil) and prospects for its clinical use. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(8):21-31
Post-stroke cognitive impairment in young patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(8):92-96
Reco­gnan (citicoline) prescribing in cere­brovascular diseases and type 2 diabetes mellitus patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(9):23-27

Optimization of the choice of neuroprotective therapy regimens in patients with CVD, taking into account the synergism of drug interactions, is basic in real clinical practice. Unfortunately, in modern pharmacology there is no unified way to establish the synergistic spectrum of action of drugs, which would allow systematic investigation of the effects of combinations of drugs. By the method of studying the subtle mechanisms of action, combinations of drugs that are as synergistic as possible (summation and potentiation of effects) for various therapies of neurological diseases are proposed. Examples of rational neuroprotection are considered on the preparations Cortexin, citicoline, antioxidants.

Keywords:

neuroprotection
synergism
agonist substances
summation
potentiation
Cortexin
citicoline
antioxidants

Authors:

Putilina M.V.

Pirogov Russian National Research Medical University

Teplova N.V.

Pirogov Russian National Research Medical University

Received:

05.04.2022

Accepted:

06.04.2022

List of references:

  1. Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601-615.  https://doi.org/10.1038/s41591-021-01283-z
  2. Global, regional, and national burden of stroke and its risk factors, 1990—2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2021;20:795-820.  https://doi.org/10.1016/S1474-4422(21)00252-0
  3. Tong X, Yang Q, Ritchey MD, et al. The Burden of Cerebrovascular Disease in the United States. Prev Chronic Dis. 2019;16:180411. external icon https://doi.org/10.5888/pcd16.180411
  4. Federal State Statistics Service. (In Russ.). https://rosstat/gov/ru
  5. Report «World demographic prospects: revised edition of 2021». World Population Prospects: 2021. (In Russ.). https://www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/files/undesa_pd_2021_egm_wpp2022_session_
  6. Oganov RG, Simanenkov VI, Bakulin IG, et al. Comorbidities in clinical practice. Algorithms diagnostics and treatment. Cardiovas Ther Prevention. 2019;18(1):5-66. (In Russ.). https://doi.org/10.15829/1728-8800-2019-1-5-66
  7. Melissa M, Favreault D, Richard W. The Risk and Costs of Severe Cognitive Impairment at Older Ages: Literature Review and Projection Analyses, Urban Institute. 2021. https://aspe.hhs.gov/reports/risk-costs-severe-cognitive-impairment-older-ages-literature-review-projection-analyses-0
  8. Chang RCC, Ho YS. Introductory Chapter: Concept of Neuroprotection — A New Perspective, Neuroprotection. Intech Open. 2019;23(5):274636. https://doi.org/10.5772/intechopen.85631
  9. Crupi R, Impellizzeri D, Cuzzocrea S. Role of Metabotropic Glutamate Receptors in Neurological Disorders. Front Mol Neurosci. 2019;12:20-28.  https://doi.org/10.3389/fnmol.2019.00020
  10. Putilina MV. Combined therapy of cerebrovascular disorders with neuroprotectors. S.S. Korsakov Journal of Neurology and Psychiatry = Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2016;116(11):58-63. (In Russ.). https://doi.org/10.17116/jnevro201611611158-63
  11. Rodriguez C, Agulla J, Delgado-Esteban M. Refocusing the Brain: New Approaches in Neuroprotection Against Ischemic Injury. Neurochem Res. 2021;46:51-63.  https://doi.org/10.1007/s11064-020-03016-z
  12. Satyanarayana G, Chakradhar D, Melvin S. Neuroprotective agents in Acute Ischemic Stroke — A Reality Check. Biomedicine & Pharmacotherapy. 2019;109:2539-2547. https://doi.org/10.1016/j.biopha.2018.11.041
  13. Putilina MV, Teplova NV. Rational pharmacotherapy of chronic cerebral ischemia. clinical guidelines. Moscow: MEDpress-inform; 2019;475. (In Russ.).
  14. Barinov EF, Statinova EA, Sokhina VS, Faber TI. Risks of progression of cerebrovascular pathology associated with the activity of the brain purinergic system. S.S. Korsakov Journal of Neurology and Psychiatry = Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2020;120(10):118-124. (In Russ.). https://doi.org/10.17116/jnevro2020120101118
  15. Sharma H, Sharma A. Neuromodulation as a basic platform for neuroprotection and repair after spinal cord injury. Prog Brain Res. 2021;266:269-300.  https://doi.org/10.1016/bs.pbr.2021.06.012
  16. Robson F. Receptors P1 and P2 as Targets for Drug Therapy in Humans. Intech Open. 2020.10.5772/intechopen. https://doi.org/10.5772/intechopen.78115
  17. Gromova OA, Torshin IYu, Putilina MV, et al. Choice of neuroprotective therapy regimens in patients with chroniccerebral ischemia, taking into account the synergy of drug interactions. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2020;120(8):42-50. (In Russ.). https://doi.org/10.17116/jnevro202012008142
  18. Torshin IY, Rudakov KV. Combinatorial analysis of the solvability properties of the problems of recognition and completeness of algorithmic models. part 1: factorization approach. Pattern Recognition and Image Analysis (Advances in Mathematical Theory and Applications). 2017;27(1):16-28. 
  19. Wambaugh M, Denham S, Ayala M, et al. Synergistic and antagonistic drug interactions in the treatment of systemic fungal infections. eLife Sciences. 2020;9:23-29.  https://doi.org/10.7554/eLife.54160
  20. Putilina MV. Complex neuroprotective therapy of the consequences of chronic brain ischemia. Medical Council. 2010;9-10:92-97. (In Russ.).
  21. Chernykh AI, Komleva YK, Gorina YV, et al. Pro-inflammatory phenotype of perivascular astroglia and CD133+ progenitor cells of endotheliocytes in murine model of Alzheimer’s disease. Fundamental and Clinical Medicine. 2018;3(1):6-15. (In Russ.). https://doi.org/10.23946/2500-0764-2018-3-1-6-15
  22. Lima G, Doorduin J, Klein HC. Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation. Mol Neurobiol. 2019;56:3295-3312. https://doi.org/10.1007/s12035-018-1283-6
  23. Hannan MA, Dash R, Sohag AAM, et al. Neuroprotection Against Oxidative Stress: Phytochemicals Targeting TrkB Signaling and the Nrf2-ARE Antioxidant System. Front Mol Neurosci. 2020;13:116.  https://www.frontiersin.org/articles/10.3389/fnmol.2020.00116/full
  24. Zhou X, Smith QR, Liu X. Brain-penetrating peptides and peptide-drug conjugates for overcoming the blood-brain barrier and combating diseases of the central nervous system. WIRES Nanomed Nanobiotechnol. 2021;e1695. https://doi.org/10.1002/wnan.1695
  25. Soudy R, Kimura R, Patel A. Short amylin receptor antagonist peptides improve memory deficits in Alzheimer’s disease mouse model. Sci Rep. 2019;9:10942. https://doi.org/10.1038/s41598-019-47255-9
  26. Lee J, Kim C. Peptide Materials for Smart Therapeutic Applications. Macromol Res. 2021;29:2-14.  https://doi.org/10.1007/s13233-021-9011-x
  27. Shang N, Meram C, Bandara N, Wu J. Protein and Peptides for Elderly Health. Adv Protein Chem Struct Biol. 2018;112:265-308.  https://doi.org/10.1016/bs.apcsb.2018.03.003
  28. Tyurenkov IN, Kurkin DV, Kalatanova AV, et al. Comparative study of protective effects of Cortexin, Cerebrolysin and Actovegin on memory impairment, cerebral circulation and morphological changes in the hippocampus of rats with chronic brain ischemia. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2020;120(8):83-89. (In Russ.). https://doi.org/10.17116/jnevro202012008183
  29. Putilina MV, Mutovina ZYu, Kurushina OV, et al. Determination of the prevalence of postcovid syndrome and assessment of the effectiveness of the drug Cortexin in the treatment of neurological disorders in patients with postcovid syndrome. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2022;122(1):84-90. (In Russ.). https://doi.org/10.17116/jnevro202212201184
  30. Fedin AI, Bel’skaia GN, Kurushina OV, et al. Dose-dependent effects of cortexin in chronic cerebral ischemia (results of a multicenter randomized controlled study). Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2018;118(9):35-42.  https://doi.org/10.17116/jnevro201811809135
  31. Yakovlev AA, Gulyaeva NV. Molecular partners of cortexin in the brain. Neurochemistry. 2017;33:91-96. (In Russ.). https://doi.org/10.1134/S1819712416040164
  32. Kurkin D, Bakulin D, Morkovin E, et al. Neuroprotective action of Cortexin, Cerebrolysin and Actovegin in acute or chronic brain ischemia in rats. PLoS ONE. 2021;16(7):E0254493. https://doi.org/10.1371/journal.pone.0254493
  33. Putilina MV. A personalized selection of choline precursors in evidence — based medicine. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2020;120(6):144-151. (In Russ.). https://doi.org/10.17116/jnevro2020120061144
  34. Martí‐Carvajal A, Valli C, Solà I, et al. Citicoline for treating people with acute ischemic stroke. Cochrane Systematic Review. Cochrane Database Syst Rev. 2020;8(8):CD013066. https://doi.org/10.1002/14651858.CD013066.pub2
  35. Mashin VV, Belova LA, Bakhtogarimov IR, et al. Multicenter observational program for evaluating the effectiveness of the drug rekogan (citicoline) in the correction of cognitive impairment in patients with chronic cerebrovascular pathology. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2017;117(8):39-43. (In Russ.).
  36. Petrova D, Maslarov D, Angelov I, Zekin D. Analysis of therapeutic efficacy of citicoline in patients with vertigo of central origin and vascular aetiology. Am J Neuroprotec Neuroregen. 2012;4(1):1-8.  https://doi.org/10.1166/ajnn.2012.1043

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.